Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $40 From $44, Maintains Outperform Rating
Rocket Pharmaceuticals Shares Are Trading Lower After the Company Announced a $165 Million Upsized Public Offering of 13.2 Million Shares at $12.50 per Share.
Rocket Pharmaceuticals Intends To Offer And Sell $150M Of Shares Of Its Common Stock In Public Offering
Express News | Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
